<DOC>
	<DOCNO>NCT00055133</DOCNO>
	<brief_summary>Paxceed™ develop Angiotech Pharmaceuticals , Inc. treatment Rheumatoid Arthritis ( RA ) . The main objective study determine effectiveness treatment Paxceed™ patient RA . In RA , increase cell growth change cell function . The active substance Paxceed™ , paclitaxel , undergone clinical study cancer chemotherapeutic agent demonstrate usefulness agent stop growth cell block certain type cell function associate RA . Because effect , think Paxceed™ might alter destructive course RA .</brief_summary>
	<brief_title>A Study Using Intravenous Paxceed™ Treat Patients With Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>( ) Signed informed consent accordance applicable regulation ( ii ) Males female age 21 70 year inclusive ( iii ) Must fail least one DMARD ( iv ) Rheumatoid Arthritis fulfil 1987 ACR revise criterion ( v ) Active RA define : ≥6 swell ≥9 tender joint CRP ≥0.8 mg/dL morning stiffness ≥45 minute ( vi ) If female child bear potential , must : negative serum pregnancy test , use two form effective method contraception ( one form barrier method ) surgically incapable bearing child abstinent . If male heterosexual , must : agree use condom spermicide throughout study least 12 week follow last infusion . vasectomy acceptable form contraception males partner female ( vii ) Adequate venous access define Principal Investigator ( viii ) If take nonsteroidal antiinflammatory medication , must stable regimen four week prior Screening visit ( ix ) If take prednisone ( ≤ 10 mg ) equivalent , must stable regimen four week prior Screening visit ( ) Prior current treatment alkylating agent , radiation ( ii ) Treatment colchicine within six month prior Screening ( iii ) Experimental antirheumatic drug within 90 day ( five halflives , whichever long ) prior screen ( iv ) DMARD therapy four week prior Baseline visit ( v ) Intraarticular corticosteroid four week prior Screening visit ( vi ) Bedridden wheelchair bound patient ( vii ) Pregnant lactate female ( viii ) Interstitial lung disease ( ix ) Clinically significant cardiac risk factor , include history congestive heart failure , angina , myocardial infarction within previous six month ( x ) History malignancy , except ( ) basal cell carcinoma skin situ cervical carcinoma excise recurrence treatment within last five year , ( b ) lowgrade prostate cancer ( xi ) Major organ allograft , uncontrolled cardiac , hepatic , pulmonary , renal central nervous system disease , know clot deficiency , illness increase undue risk patient ( xii ) History anaphylactic reaction ( xiii ) WBC count &lt; 4,000/mm3 ; Neutrophils &lt; 2,000/mm3 ; Platelet count &lt; 125,000/mm3 ; hemoglobin &lt; 9g/dL ; creatinine &gt; 1.4 time upper limit normal ; liver function test &gt; 1.2 time upper limit normal ( xiv ) Presence Hepatitis B Surface antigen ( HbsAg ) , Hepatitis C antibody ( HCVAb ) , and/or Hepatitis C quantitative assay , history hepatitis ( autoimmune hepatitis ) within one year prior Screening ( xv ) Presence confound illness syndrome may interfere proper evaluation efficacy , autoimmune disease , psoriatic arthritis , lupus scleroderma ( xvi ) Patients determine investigator ( e.g. , know probable alcohol drug abuse ) unreliable followup</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>July 2008</verification_date>
	<keyword>rheumatoid arthritis</keyword>
	<keyword>Paxceed</keyword>
	<keyword>Micellar Paclitaxel</keyword>
</DOC>